DelSiTech signs License Agreement with Bayer Innovation
DelSiTech has signed a license agreement with Bayer Innovation. The agreement enables Bayer the exclusive rights to use the unique and proprietary DelSiTech ® drug delivery technology for fiber applications in the fields of wound care and certain other applications.Under the terms of the agreement DelSiTech will receive a signing fee, milestone payments and further royalties for future sales of the products using the DelSiTech technology. The agreement contains also an option for further collaboration.
Dr. Harry Jalonen, CEO of DelSiTech said: “We are proud to have a global player like Bayer as our customer. Wound care is an utmost interesting indication area with high unmet medical need. At the same time we are happy to find new applications for our technology, which originally was developed for controlled drug release”.
delsitech.com
delsitech.com